TY - JOUR
T1 - Adversomics
T2 - The emerging field of vaccine adverse event immunogenetics
AU - Poland, Gregory A.
AU - Ovsyannikova, Inna G.
AU - Jacobson, Robert M.
N1 - Funding Information:
Supported by the National Institutes of Health grants AI 33144, AI 48793, and AI 40065 for our vaccine immunogenetics studies.
PY - 2009/5
Y1 - 2009/5
N2 - We believe that adversomics (the immunogenetics and immunogenomics of vaccine adverse events at the individual and population level, respectively) is critical to understanding and preventing serious adverse vaccine-related events, developing the next generation of vaccines, and to improving public confidence in vaccine safety. Significant difficulties in the growth of the field of vaccine immunogenetics include the difficulty of studying large enough numbers of subjects (rare AEs are, by definition, rare), lack of research funding, the complexity and extensive polymorphic nature of immune response genes, statistical issues of multiple comparisons and statistical power, issues of multigenic and other gene interactions such as complementation and epigenetic DNA modifications, and gender, racial, and ethnic differences. Nonetheless, the field of adversomics is growing due to scientific interest in understanding the basis for vaccine reactions, "push" from the growing field of individualized medicine, and consumer demand for safer vaccines. The capability to reproduce statistical associations in independent population-based studies remains essential to assessing the generalization of such studies. Clearly more comprehensive studies are needed to determine if there are associations between genetic variations among individuals and susceptibility to serious adverse events in response to vaccination. These factors combined with technologic ability will lead to a new era in vaccinology and better, safer vaccines.
AB - We believe that adversomics (the immunogenetics and immunogenomics of vaccine adverse events at the individual and population level, respectively) is critical to understanding and preventing serious adverse vaccine-related events, developing the next generation of vaccines, and to improving public confidence in vaccine safety. Significant difficulties in the growth of the field of vaccine immunogenetics include the difficulty of studying large enough numbers of subjects (rare AEs are, by definition, rare), lack of research funding, the complexity and extensive polymorphic nature of immune response genes, statistical issues of multiple comparisons and statistical power, issues of multigenic and other gene interactions such as complementation and epigenetic DNA modifications, and gender, racial, and ethnic differences. Nonetheless, the field of adversomics is growing due to scientific interest in understanding the basis for vaccine reactions, "push" from the growing field of individualized medicine, and consumer demand for safer vaccines. The capability to reproduce statistical associations in independent population-based studies remains essential to assessing the generalization of such studies. Clearly more comprehensive studies are needed to determine if there are associations between genetic variations among individuals and susceptibility to serious adverse events in response to vaccination. These factors combined with technologic ability will lead to a new era in vaccinology and better, safer vaccines.
UR - http://www.scopus.com/inward/record.url?scp=67649550233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649550233&partnerID=8YFLogxK
U2 - 10.1097/INF.0b013e3181a6a511
DO - 10.1097/INF.0b013e3181a6a511
M3 - Article
C2 - 19395950
AN - SCOPUS:67649550233
SN - 0891-3668
VL - 28
SP - 431
EP - 432
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
IS - 5
ER -